Feb 14 |
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
|
Feb 6 |
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
|
Feb 6 |
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
|
Jan 31 |
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
|
Jan 24 |
Gain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should Know
|
Jan 12 |
Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential
|
Jan 2 |
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
|
Dec 22 |
Doubling Down On Gain Therapeutics
|
Dec 19 |
Gain Therapeutics files to sell 744,026 shares of common stock for holders
|
Dec 14 |
Bears are Losing Control Over Gain Therapeutics, Inc. (GANX), Here's Why It's a 'Buy' Now
|